Pfizer tests new injection sites for Weight-Loss drug in Early-Stage study
NCT ID NCT07400679
First seen Feb 19, 2026 · Last updated May 06, 2026 · Updated 11 times
Summary
This early-stage study is testing a single dose of an experimental medicine called PF-08653944 in 54 overweight or obese adults. The goal is to see how the drug is absorbed when injected into the thigh, upper arm, or abdomen. Researchers will also monitor safety through blood tests and vital signs. This study does not aim to treat or cure obesity, but to gather information for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New Haven Clinical Research Unit
RECRUITINGNew Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.